Terapia de ondas de choque lineales en el tratamiento de la disfunción eréctil / Linear shock wave therapy in the treatment of erectile dysfunction

Introducción: La terapia de ondas de choque lineales (LSWT) es una nueva terapia no invasiva que utiliza ondas de choque de baja intensidad para inducir la angiogénesis local controlada y mejorar significativamente la función eréctil. Objetivo: Evaluar la eficacia de la LSWT en hombres con disfunción eréctil vasculogénica (DE) en un centro de atención de tercer nivel. Material y métodos: Se incluyeron 15 hombres de edades comprendidas entre 45 y 70 años, sexualmente activos con DE vascular leve y moderada, evaluados con el índice internacional de función eréctil (IIEF). El estudio se realizó en 3 etapas: detección, tratamiento y seguimiento. Recibieron 4 sesiones de LSWT semanales (RENOVA®) 5.000 ondas (0,09 mJ/mm2). La función eréctil se evaluó con IIEFF-EF, Perfil del encuentro sexual (SEP) y Cuestionario de evaluación global (GAQ) al mes y a los 6 meses después del tratamiento. Resultados: La tasa de éxito fue del 80% (12/15). Pacientes con DE leve 40% y DE moderada 60%. Se encontró una asociación positiva entre el IIEF-basal (promedio 14,23 pts) y IIEF un mes y 6 meses después del tratamiento (19,69 pts) una diferencia de 5,46 puntos (p < 0,013). Conclusiones: La factibilidad y tolerabilidad de este tratamiento, y sus características potenciales de rehabilitación, hacen que pueda ser una nueva opción terapéutica atractiva para pacientes con DE

Introduction: Linear Shock Wave Therapy (LSWT) is a new noninvasive therapy that uses low-intensity shock waves to induce local angiogenesis promising modality in the treatment of erectile dysfunction (ED). Objective: To evaluate the effectiveness of LSWT in men with vasculogenic erectile dysfunction (ED), in a Tertiary Care Center. Material and methods: Included 15 men aged 45-70 years, sexually active with mild and moderate vascular ED evaluated with the International Index of Erectile Function (IIEF). The study was conducted in three stage: screening, treatment and results. Treatment stage: 4 weekly sessions LSWT (RENOVA ®) 5000 waves (.09 mJ/mm2). Erectile function was assessed with IIEFF-EF, SEP (Sexual Encounter Profile) and GAQ (Global Assessment Questions) at one and six months after treatment. Results: The rate of success was 80% (12/15). Patients with mild ED (6/15) 40% and moderate ED (9/15) 60%. We found a positive association between IIEF-Basal (average 14.23 pts) and IIEF at one month and six months after therapy (19.69 pts) a difference of 5.46 pts. (P < .013). Conclusions: The feasibility and tolerability of this treatment, and rehabilitation potential features, make it this an attractive new treatment option for patients with ED

Linear shock wave therapy in the treatment of erectile dysfunction.

INTRODUCTION: Linear Shock Wave Therapy (LSWT) is a new noninvasive therapy that uses low-intensity shock waves to induce local angiogenesis promising modality in the treatment of erectile dysfunction (ED). OBJECTIVE: To evaluate the effectiveness of LSWT in men with vasculogenic erectile dysfunction (ED), in a Tertiary Care Center. MATERIAL AND METHODS: Included 15 men aged 45-70 years, sexually active with mild and moderate vascular ED evaluated with the International Index of Erectile Function (IIEF). The study was conducted in three stage: screening, treatment and results. Treatment stage: 4 weekly sessions LSWT (RENOVA ®) 5000 waves (.09mJ/mm(2)). Erectile function was assessed with IIEFF-EF, SEP (Sexual Encounter Profile) and GAQ (Global Assessment Questions) at one and six months after treatment. RESULTS: The rate of success was 80% (12/15). Patients with mild ED (6/15) 40% and moderate ED (9/15) 60%. We found a positive association between IIEF-Basal (average 14.23 pts) and IIEF at one month and six months after therapy (19.69 pts) a difference of 5.46 pts. (P<.013). CONCLUSIONS: The feasibility and tolerability of this treatment, and rehabilitation potential features, make it this an attractive new treatment option for patients with ED.